Overview

Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:
0

Participant gender:
All

Summary

This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shanghai Changzheng Hospital

Treatments:

Trastuzumab

Criteria

Inclusion Criteria:

Patients should be histologically diagnosed with metastatic colorectal cancer or
postoperative recurrence; Patients with ALK mutation(including mutation, fusion,
rearrangements ); Patients have measurable lesions; Patients are not available for targeted
therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3
weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be
18-25 years; Performance status should be 0-2; Life expectancy should be more than 12
weeks;

Exclusion Criteria:

Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to
experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain
metastases; Patients with chemotherapy contraindication; Patients could not tolerate
chemotherapy; Patients have secondary primary tumor.